admin – Page 555 – Get News Story

Top Real Estate Listing Agent in Cape Coral, FL, Highlights Strategic Pricing as Key Factor in Today’s Southwest Florida Market

Cape Coral, FL – As Southwest Florida’s real estate market becomes more measured, success increasingly depends on strategic approach rather than speed alone. Proper pricing and professional presentation have emerged as critical factors separating listings that sell smoothly from those experiencing extended market time.

Jenn Spears, Cape Coral, FL Realtor, reports that overpricing continues to result in longer market exposure, while competitively priced properties generate stronger buyer interest from the start. “Today’s buyers are analytical,” explains Ashworth. “They compare multiple properties carefully before making decisions, which means pricing accuracy matters more than ever.”

Jenn Spears, Realtor agent in Cape Coral, FL, emphasizes that presentation quality significantly influences perceived value. “Professional marketing, staging, and attention to property condition help homes stand out in a market where buyers have options,” says Spears. “Sellers who adapt to current expectations consistently see stronger outcomes.” Data shows that properly priced listings receive offers an average of three weeks faster than overpriced comparables in the same neighborhoods.

Re/Max Realty Team: Bob Ashworth PA & Jenn Spears Real Estate Agents in Cape Coral FL specializes in developing customized marketing strategies that showcase properties effectively. As an experienced real estate listing agent in Cape Coral, FL, Jenn Spears and the team provides honest market assessments that help sellers establish realistic pricing from day one.

Their detail-oriented approach includes comprehensive market analysis, professional photography, and strategic positioning that attracts qualified buyers. As a respected Cape Coral, FL Realtor agent, Spears brings certified negotiation expertise to every transaction, ensuring clients achieve optimal results regardless of market conditions.

“Preparation and transparency are what drive success in today’s environment,” notes Spears. “Sellers who work with knowledgeable professionals and price strategically position themselves for smooth transactions.”

Considering selling your Southwest Florida property? Visit http://bobashworthrealty.com/ to connect with real estate professionals who combine market expertise with proven marketing strategies. Re/Max Realty Team delivers results through straightforward communication and commitment to client satisfaction from first meeting through closing.

Media Contact
Company Name: Re/Max Realty Team: Bob Ashworth PA & Jenn Spears Real Estate Agent in Cape Coral FL
Contact Person: Bob Ashworth
Email: Send Email
Phone: +1 239-898-2716
Address:2326 Del Prado Blvd S
City: Cape Coral
State: Florida
Country: United States
Website: bobashworthrealty.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Listing Agent in Cape Coral, FL, Highlights Strategic Pricing as Key Factor in Today’s Southwest Florida Market

TaxTools AI Launches Advanced AI-Powered Platform to Simplify U S Salary Planning and Tax Calculations

Understanding how much of your salary you actually take home can be surprisingly difficult. In the United States, federal income tax, state tax, local tax, and payroll deductions all interact to shape your final paycheck. For employees, freelancers, and even employers, miscalculating take-home pay can lead to budgeting mistakes, tax surprises, or confusion during salary negotiations. This is why accurate, easy-to-use digital tools have become essential. TaxTools AI positions itself as a practical solution, offering clear and reliable tax and paycheck calculations tailored to U.S. tax rules.

Why Accurate Paycheck Calculations Matter

Gross salary figures are often misleading. A job offer may look attractive on paper, but without understanding deductions, it is difficult to evaluate its real value. Federal income tax brackets, state-specific tax systems, Social Security, Medicare, and optional withholdings all reduce gross income before it reaches your bank account.

TaxTools AI addresses this challenge by acting as a centralized platform for salary and tax estimation. Instead of manually piecing together tax rates and deduction formulas, users can rely on a single interface that reflects current U.S. tax structures. This is particularly useful in a country where tax obligations vary significantly from state to state.

What Is TaxTools AI?

At its core, TaxTools is an online tax and paycheck calculator designed to help users estimate federal and state taxes accurately. The platform functions as a US salary calculator, income tax calculator, paycheck calculator, and tax estimator, all in one place. By entering income details, users can instantly see how taxes and deductions affect their take-home pay.

TaxTools AI focuses on simplicity without sacrificing accuracy. It breaks down results in a way that is easy to understand, making it accessible to people who may not be familiar with tax terminology. Whether you are planning your monthly budget or checking how a raise will affect your net income, the platform provides quick, actionable insights.

Federal and State Taxes in One Place

One of the biggest pain points for U.S. workers is navigating the combination of federal and state taxes. While federal income tax rules apply nationwide, each state has its own tax structure. Some states impose progressive income taxes, others use flat rates, and a few have no state income tax at all.

TaxTools AI integrates these layers into a single calculation process. Users can estimate how federal income tax interacts with state-level deductions, giving them a clearer picture of their true earnings. This approach reduces guesswork and helps users avoid underestimating or overestimating their take-home pay.

California Paycheck Calculator: Clarity in a High-Tax State

California is known for its complex and relatively high tax system. Between federal withholding, state income tax, and mandatory deductions, understanding a California paycheck can be challenging. TaxTools AI offers a dedicated California paycheck calculator that reflects 2025 state tax rates, federal withholding, and standard deductions.

This calculator is especially helpful for professionals considering relocation, negotiating salaries, or transitioning between jobs within California. By seeing an instant salary breakdown, users can better understand how much income they will actually receive after taxes, which is essential for managing living costs in one of the most expensive states in the country.

New York Paycheck Calculations Made Simple

New York presents its own set of complexities, particularly for employees working in or around New York City. In addition to federal and state income tax, some workers must account for NYC or Yonkers local taxes. TaxTools AI simplifies this process with a New York paycheck calculator that includes these local considerations.

By accounting for city-level taxes alongside state and federal deductions, the tool provides a realistic estimate of net pay. This level of detail is especially valuable for professionals in finance, media, and technology sectors where compensation structures can vary widely and bonuses or overtime may affect withholding.

Designed for Everyday Financial Decisions

TaxTools AI is not only for tax season. Its real value lies in everyday financial planning. Common use cases include:

Comparing job offers across different states
Estimating take-home pay before accepting a promotion
Adjusting withholding expectations after a salary change
Planning monthly expenses based on realistic net income

Because the tool delivers instant results, users can experiment with different salary scenarios and better understand how changes affect their finances.

User-Friendly and Accessible

One of the strengths of TaxTools AI is its intuitive design. The platform does not require advanced tax knowledge or professional experience. Users simply enter basic income information and receive clear results. This makes it suitable for a wide range of users, including students entering the workforce, freelancers managing variable income, and full-time employees reviewing their paychecks.

The emphasis on clarity also helps reduce anxiety around taxes. Instead of opaque calculations, users see transparent breakdowns that explain how deductions are applied.

Supporting Smarter Financial Planning

In an environment where living costs continue to rise and tax rules evolve, understanding net income is essential. Tools like TaxTools AI empower users to make informed decisions based on accurate data rather than assumptions. This can lead to better budgeting, more confident salary negotiations, and fewer surprises at tax time.

For employers and HR professionals, such tools can also support clearer communication around compensation, helping teams understand the real value of salary packages.

A Practical Tool for Modern Workers

TaxTools AI reflects a broader shift toward digital financial tools that prioritize accessibility and accuracy. Combining federal and state tax calculations into a single platform, it reduces complexity and saves time. Whether you are calculating a California paycheck, estimating New York take-home pay, or simply checking how federal taxes affect your income, the platform provides a reliable starting point.

In a country with one of the most intricate tax systems in the world, having a dependable online tax calculator is no longer a luxury. It is a necessity. TaxTools AI meets this need by offering clear, fast, and accurate insights into how much you really earn, helping users stay informed and financially confident throughout the year.

Media Contact
Company Name: TaxTools AI
Email: Send Email
Country: United States
Website: https://taxtools.ai/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: TaxTools AI Launches Advanced AI-Powered Platform to Simplify U S Salary Planning and Tax Calculations

Head and Neck Cancer Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Head and Neck Cancer Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Head and Neck Cancer pipeline landscape. It covers the Head and Neck Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Head and Neck Cancer Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Head and Neck Cancer Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-pipeline-insight

Key Takeaways from the Head and Neck Cancer Pipeline Report

On February 04, 2026- Merck Sharp & Dohme LLC announced phase III study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS).
On January 28, 2026- Dana-Farber Cancer Institute initiated a study is to evaluate effectiveness (how well the drug/s work) of Nivolumab or Nivolumab combined with Ipilimumab prior to standard of care surgery. Nivolumab and Ipilimumab are types of immunotherapy. Immunotherapy works by encouraging the body’s own immune system to attack cancer cells. Both nivolumab and Ipilimumab have been demonstrated to activate the immune system to attack cancer cells in laboratory studies and in patients with different types of cancers.
On January 12, 2026- Boehringer Ingelheim conducted a phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.
DelveInsight’s Head and Neck Cancer Pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Head and Neck Cancer treatment.
The leading Head and Neck Cancer Companies such as Merus, Bicara Therapeutics, Kura Oncology, Inc., Theriva Biologics, Nykode Therapeutics ASA, Cue Biopharma, BioNTech SE, Exelixis, AstraZeneca, Johnson & Johnson, Intragel, AbbVie, IOVANCE Biotherapeutics, Inc., Immutep Limited, Repertoire Immune Medicines, Pyxis Oncology, Inc., ALX Oncology, iTeos Therapeutics, AVEO Oncology, Akeso Biopharma, Coherus BioSciences, Inc., Flamingo Therapeutics, Adlai Nortye Ltd., Hibercell Inc., Elpiscience Biopharmaceuticals, KSQ Therapeutics, and Transgene and others.
Promising Head and Neck Cancer Therapies such as RiMO-301, Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug, Methotrexate, Afatinib, and others.

Want to know which companies are leading innovation in Head and Neck Cancer? Dive into the full pipeline insights @ Head and Neck Cancer Clinical Trials Assessment

The Head and Neck Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Head and Neck Cancer Pipeline Report also highlights the unmet needs with respect to the Head and Neck Cancer.

Head and Neck Cancer Overview

Head and neck cancer encompasses a diverse group of malignancies that arise in the squamous cells lining the mucosal surfaces of the oral cavity, pharynx, larynx, nasal cavity, and paranasal sinuses, as well as in the salivary glands and other structures within the head and neck region. These cancers are most commonly squamous cell carcinomas and are strongly associated with risk factors such as tobacco use, alcohol consumption, and infection with high-risk strains of human papillomavirus (HPV), particularly HPV-16.

Head and Neck Cancer Emerging Drugs Profile

Petosemtamab: Merus

Petosemtamab, or MCLA-158, is a Biclonics® low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). Petosemtamab is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity. Petosemtamab granted Breakthrough Therapy designation by the US FDA for 1L PD-L1 positive head and neck squamous cell carcinoma. Currently, the drug is in Phase III stage of its development for the treatment of Head and Neck cancer (HNC).

Ficerafusp alfa: Bicara Therapeutics

Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-b signaling within the tumor microenvironment. Currently, the drug is in Phase II/III stage of its development for the treatment of Head and Neck cancer (HNC).

Tipifarnib: Kura Oncology, Inc

Tipifarnib, is an inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development. In extensive clinical trials, tipifarnib has shown a well-established safety profile and compelling and durable anti-cancer activity in certain patient subsets. Preclinical and clinical data suggest that, in the appropriate context, tipifarnib has the potential to provide significant benefit to cancer patients with limited treatment options. In addition to its development program in solid tumors with HRAS mutations, Kura has identified potential biomarkers of activity for tipifarnib in hematologic malignancies, including peripheral T-cell lymphomas (PTCL), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Currently, the drug is in Phase II stage of its development for the treatment of Head and Neck cancer (HNC).

VCN-01: Theriva Biologics

VCN-01 (zabilugene almadenorepvec) is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to over 140 patients to date in clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection). Currently, the drug is in Phase I/II stage of its development for the treatment of Head and Neck cancer (HNC).

VB10.16: Nykode Therapeutics ASA

VB10.16 is a potentially first-in-class off-the-shelf therapeutic DNA-based cancer vaccine candidate in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers. The cancer vaccine is designed based on Nykode’s Vaccibody™ technology platform of targeting antigens to antigen presenting cells. The vaccine-induced significant HPV16-specific T cell responses in clinical studies that were correlated with clinical responses. Currently, the drug is in Phase I/II stage of its development for the treatment of Head and Neck cancer (HNC).

CUE 101: Cue Biopharma

CUE-101 is a fusion protein designed to activate and expand tumor-specific T cells, directly in the patient’s body, that target Human Papilloma 16 (HPV16)-driven malignancies. It contains IL-2 and a pMHC composed of HLA-A*02:01 complexed with a dominant peptide derived from the E7 protein of human papilloma virus 16 (HPV 16-E7). CUE-101 is the lead immuno-oncology drug developed within the IL-2 based CUE-100 framework from Cue Biopharma’s novel Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform technology. In November 2018, LG Chem Life Sciences partnered with Cue Biopharma to develop and commercialize cancer immunotherapy drugs based on the Immuno-STAT platform technology. Currently, the drug is in Phase I stage of its development for the treatment of Head and Neck cancer (HNC).

If you’re tracking ongoing Head and Neck Cancer Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Head and Neck Cancer Treatment Drugs

The Head and Neck Cancer Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Head and Neck Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Head and Neck Cancer Treatment.
Head and Neck Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Head and Neck Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Head and Neck Cancer market.

Head and Neck Cancer Companies

Merus, Bicara Therapeutics, Kura Oncology, Inc., Theriva Biologics, Nykode Therapeutics ASA, Cue Biopharma, BioNTech SE, Exelixis, AstraZeneca, Johnson & Johnson, Intragel, AbbVie, IOVANCE Biotherapeutics, Inc., Immutep Limited, Repertoire Immune Medicines, Pyxis Oncology, Inc., ALX Oncology, iTeos Therapeutics, AVEO Oncology, Akeso Biopharma, Coherus BioSciences, Inc., Flamingo Therapeutics, Adlai Nortye Ltd., Hibercell Inc., Elpiscience Biopharmaceuticals, KSQ Therapeutics, and Transgene and others.

Head and Neck Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Head and Neck Cancer Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Head and Neck Cancer Pipeline Report covers it all – check it out now @ Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Head and Neck Cancer Pipeline Report

Coverage- Global
Head and Neck Cancer Companies- Merus, Bicara Therapeutics, Kura Oncology, Inc., Theriva Biologics, Nykode Therapeutics ASA, Cue Biopharma, BioNTech SE, Exelixis, AstraZeneca, Johnson & Johnson, Intragel, AbbVie, IOVANCE Biotherapeutics, Inc., Immutep Limited, Repertoire Immune Medicines, Pyxis Oncology, Inc., ALX Oncology, iTeos Therapeutics, AVEO Oncology, Akeso Biopharma, Coherus BioSciences, Inc., Flamingo Therapeutics, Adlai Nortye Ltd., Hibercell Inc., Elpiscience Biopharmaceuticals, KSQ Therapeutics, and Transgene, and others.
Head and Neck Cancer Therapies- RiMO-301, Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug, Methotrexate, Afatinib, and others.
Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Head and Neck Cancer Treatment landscape in this detailed analysis @ Head and Neck Cancer Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Head and Neck cancer (HNC): Overview
Pipeline Therapeutics
Therapeutic Assessment
Head and Neck cancer (HNC)– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Petosemtamab: Merus
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tipifarnib: Kura Oncology, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CUE 101: Cue Biopharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Head and Neck cancer (HNC) Key Companies
Head and Neck cancer (HNC) Key Products
Head and Neck cancer (HNC)- Unmet Needs
Head and Neck cancer (HNC)- Market Drivers and Barriers
Head and Neck cancer (HNC)- Future Perspectives and Conclusion
Head and Neck cancer (HNC) Analyst Views
Head and Neck cancer (HNC) Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Head and Neck Cancer Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Diffuse Large B-Cell Lymphoma Clinical Trial Pipeline Accelerates as 70+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insights 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space.

Download DelveInsight’s comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight

Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report

On February 20, 2026, Merck Sharp & Dohme LLC conducted a phase 3 study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
On February 13, 2026, Tanabe Pharma Corporation initiated a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL. To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed.
On February 06, 2026- Hoffmann-La Roche announced a Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).
DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.

Access DelveInsight’s in-depth pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies

Diffuse Large B-Cell Lymphoma Emerging Drugs Profile

Brentuximab vedotin: Pfizer

Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

THOR-707: Sanofi

THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.

RNK05047: Ranok Therapeutics

RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.

BMF-219: Biomea Fusion

BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

ADI-001: Adicet Bio

ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

The Diffuse Large B-Cell Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.

Explore DelveInsight’s expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs

Diffuse Large B-Cell Lymphoma Companies

Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.

Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Drugs Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report

Coverage- Global
Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma Therapies– Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Diffuse Large B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Large B-Cell Lymphoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Brentuximab vedotin: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
THOR-707: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADI-001: Adicet Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Large B-Cell Lymphoma Key Companies
Diffuse Large B-Cell Lymphoma Key Products
Diffuse Large B-Cell Lymphoma- Unmet Needs
Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
Diffuse Large B-Cell Lymphoma Analyst Views
Diffuse Large B-Cell Lymphoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Large B-Cell Lymphoma Clinical Trial Pipeline Accelerates as 70+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Dry AMD Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Dry Age-related Macular Degeneration Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Dry Age-related Macular Degeneration (Dry-AMD) pipeline landscape. It covers the Dry Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dry Age-Related Macular Degeneration pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Dry Age-Related Macular Degeneration Pipeline. Dive into DelveInsight’s comprehensive report today! @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight

Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report

On February 04, 2026, Regenerative Patch Technologies LLC announced a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
On January 29, 2026, Hoffmann-La Roche conducted a study is evaluation of the safety and tolerability of OpRegen – Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
On January 23, 2026, Bionic Sight LLC initiated a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-escalation study; Part 2 is a dose-expansion study with dose(s) selected from Part 1 based on a benefit/risk assessment, and an untreated (sham injection) group to allow for a controlled comparison of efficacy and safety.
DelveInsight’s Dry Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for Dry Age-Related Macular Degeneration treatment.
The leading Dry Age-Related Macular Degeneration Companies such as Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics, Aviceda Therapeutics, Galimedix Therapeutics, Mitotech, Annexon, Inc., NGM Biopharmaceuticals, Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, ONL Therapeutics, and others.
Promising Dry Age-Related Macular Degeneration Pipeline Therapies such as RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Dry Age-Related Macular Degeneration Treatment Drugs

Dry Age-Related Macular Degeneration Emerging Drugs Profile

Tinlarebant (LBS-008): Belite Bio

LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins (A2E) in the eye that cause Stargardt disease and contribute to atrophic Age-related Macular Degeneration (dry AMD). The toxins are by-products of the eye’s visual cycle which are produced from vitamin A. LBS-008 works by reducing and modulating a carrier protein, Retinol-Binding Protein 4 (RBP4) that is to transport vitamin A to the eye. LBS-008 does not directly interfere with the visual cycle, and therefore is unlikely to affect the visual cycle rate. LBS-008 received US and EU orphan drug designation (ODD) in 2017 and 2018, and rare pediatric disease designation (RPD) from the FDA in 2018 for the treatment of Stargardt disease. Currently, the drug is in Phase III stage of its development for the treatment of Dry AMD.

XIFLAM: Inflammx Therapeutics

Xiflam, an orally administered NLRP3 inflammasome inhibitor with broad application that is formulated as a tablet. InflammX will initially focus on the ophthalmic indications of Diabetic Macular Edema (DME), the intermediate stage of Aged-Related Macular Degeneration (iAMD) and the Geographic Atrophy (GA) form of AMD. Xiflam’s unique mechanism of action and its ability to cross the blood-brain and blood-retinal barriers provide a novel therapeutic approach for treating retinal diseases with an orally administered tablet capable of treating both eyes simultaneously. This disruptive technology can provide a much needed clinical alternative for treating the millions of patients with diabetic retinopathy and age-related macular degeneration. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Geographic Atrophy.

OCU410: Ocugen

OCU410 (AAV-RORA) is a modifier gene therapy product candidate being developed for the treatment of dry age-related macular degeneration (Dry AMD). OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. Various genes associated with AMD are regulated by RORA. The RORA protein plays an important role in lipid metabolism and demonstrates an anti-inflammatory role, which we believe could be a potential therapeutic candidate for dry AMD based on in-vitro and in-vivo (animal model) studies. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Dry AMD.

OLX301A: OliX Pharmaceuticals

OLX301A aims to be a first-in-class therapeutics for treating both dry and wet age-related macular degeneration (AMD). The program targets a gene that plays a major role in retinal pigment epithelium (RPE) cell damage. Currently, there are no approved therapies to treat patients with both geographic atrophy (GA) and wet AMD, and one drug approved for GA is with concern regarding its efficacy. OLX301A has the potential to be a novel drug for wet AMD patients who is not responsive to conventional VEGF therapies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Dry AMD.

GS030: Gensight Biologics

GS030 is an innovative combination of two complementary components: A gene therapy product encoding a photo activatable channel rhodopsin protein, delivered via a modified AAV2 vector known as AAV2 7m8 and biomimetic goggles that stimulate the engineered retinal cells. GS030 uses optogenetics, a biologic technique that involves the transfer of a gene that encodes for a light-sensitive protein, which in turn causes neuronal cells to respond to light stimulation. GS030 includes a bio-engineered AAV2 gene therapy vector that introduces the gene of a photosensitive protein (to which we have exclusive rights in ontogenetic) into the nucleus of the target cells, in case the retinal ganglion cells, or RGCs. Currently the drug is currently in the preclinical stage of development for the treatment of Dry AMD.

The Dry Age-Related Macular Degeneration Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Dry Age-Related Macular Degeneration with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age-Related Macular Degeneration Treatment.
Dry Age-Related Macular Degeneration Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Dry Age-Related Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Age-Related Macular Degeneration market

Explore groundbreaking therapies and clinical trials in the Dry Age-Related Macular Degeneration Pipeline. Access DelveInsight’s detailed report now! @ New Dry Age-Related Macular Degeneration Drugs

Dry Age-Related Macular Degeneration Companies

Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics, Aviceda Therapeutics, Galimedix Therapeutics, Mitotech, Annexon, Inc., NGM Biopharmaceuticals, Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, ONL Therapeutics and others.

Dry Age-related Macular Degeneration (Dry-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Dry Age-Related Macular Degeneration Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Dry Age-Related Macular Degeneration Market Drivers and Barriers

Scope of the Dry Age-Related Macular Degeneration Pipeline Report

Coverage- Global
Dry Age-Related Macular Degeneration Companies- Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics, Aviceda Therapeutics, Galimedix Therapeutics, Mitotech, Annexon, Inc., NGM Biopharmaceuticals, Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, ONL Therapeutics and others.
Dry Age- Related Macular Degeneration Pipeline Therapies- RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.
Dry Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Dry Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Dry Age-Related Macular Degeneration Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Dry Age-related Macular Degeneration (Dry-AMD): Overview
Pipeline Therapeutics
Therapeutic Assessment
Dry Age-related Macular Degeneration (Dry-AMD)– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tinlarebant (LBS-008): Belite Bio
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
XIFLAM: Inflammx Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
OCU410: Ocugen
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
GS030: Gensight Biologics
Drug profiles in the detailed report…..
Inactive Products
Dry Age-related Macular Degeneration (Dry-AMD) Key Companies
Dry Age-related Macular Degeneration (Dry-AMD) Key Products
Dry Age-related Macular Degeneration (Dry-AMD)- Unmet Needs
Dry Age-related Macular Degeneration (Dry-AMD)- Market Drivers and Barriers
Dry Age-related Macular Degeneration (Dry-AMD)- Future Perspectives and Conclusion
Dry Age-related Macular Degeneration (Dry-AMD) Analyst Views
Dry Age-related Macular Degeneration (Dry-AMD) Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry AMD Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Duchenne Muscular Dystrophy Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Duchenne Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Duchenne Muscular Dystrophy Research. Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight

Key Takeaways from the Duchenne Muscular Dystrophy Pipeline Report

On February 17, 2026- Satellos Bioscience Inc. announced a phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and < 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
On February 12, 2026- Entrada Therapeutics Inc. conducted a study of the investigational medicine ENTR-601-45 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test how safe ENTR-601-45 is, learn about any side effects, and look at the potential positive effects of ENTR-601-45, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-45 and placebo are both called study treatments.
On February 10, 2026- Hoffmann-La Roche initiated a study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.
DelveInsight’s Duchenne Muscular Dystrophy pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Duchenne Muscular Dystrophy treatment.
The leading Duchenne Muscular Dystrophy Companies such as Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.
Promising Duchenne Muscular Dystrophy Therapies such as Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, and others.

Download for updates and be a part of the revolution in Musculoskeletal Care @ Duchenne Muscular Dystrophy Clinical Trials Assessment

Duchenne Muscular Dystrophy Overview

Duchenne Muscular Dystrophy (DMD) is a rare, inherited, progressive neuromuscular disorder caused by mutations in the DMD gene, which is responsible for producing dystrophin—a crucial protein that helps keep muscle cells intact. Without dystrophin, muscle fibers become fragile and easily damaged, leading to ongoing muscle weakness and degeneration. DMD typically affects young boys, with symptoms usually appearing between 2–5 years of age. Early signs include difficulty running, climbing stairs, frequent falls, enlarged calves, and delayed motor milestones. Over time, the disease progresses to affect the skeletal muscles, heart (cardiomyopathy), and lungs, making mobility increasingly challenging. Most individuals require a wheelchair in early adolescence and need respiratory and cardiac support as they grow older.

Duchenne Muscular Dystrophy Emerging Drugs

Vamorolone: Santhera

Vamorolone is a first-in-class drug candidate that binds to the same receptors as corticosteroids but modifies the downstream activity of the receptors1,2. This has the potential to ‘dissociate’ efficacy from typical steroid safety concerns and therefore could emerge as a valuable alternative to corticosteroids, the current standard of care in children and adolescent patients with DMD. There is a clear unmet medical need in this patient group as high dose corticosteroids have significant systemic side effects that detract from patient quality of life. On September 2, 2020, Santhera exercised its option and obtained worldwide rights to vamorolone in Duchenne muscular dystrophy and all other indications. Santhera and ReveraGen expect to complete the rolling NDA submission to the U.S. FDA in June 2022.

Givinostat: Italfarmaco

Givinostat, is an HDAC inhibitor (HDACi, a principle candidate, currently being developed for the treatment of DMD and BMD. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD and BMD population and to counter the disease pathogenetic events in all muscular districts.

Pamrevlumab: Fibrogen

Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer and has been granted Orphan Drug Designation (ODD) in each of these indications, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD).

The Duchenne Muscular Dystrophy Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Duchenne Muscular Dystrophy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Duchenne Muscular Dystrophy Treatment.
Duchenne Muscular Dystrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Duchenne Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Duchenne Muscular Dystrophy market.

Learn more about Duchenne Muscular Dystrophy Drugs opportunities in our groundbreaking Research and development projects @ Duchenne Muscular Dystrophy Unmet Needs

Duchenne Muscular Dystrophy Companies

Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.

Duchenne Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous

Duchenne Muscular Dystrophy Products have been categorized under various Molecule types such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Stay informed about how we’re transforming the future of musculoskeletal @ Duchenne Muscular Dystrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Duchenne Muscular Dystrophy Pipeline Report

Coverage- Global
Duchenne Muscular Dystrophy Companies- Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.
Duchenne Muscular Dystrophy Therapies- Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, and others.
Duchenne Muscular Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Duchenne Muscular Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Duchenne Muscular Dystrophy Pipeline on our website @ Duchenne Muscular Dystrophy Drugs and Companies

Table of Contents

Introduction
Executive Summary
Duchenne Muscular Dystrophy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Duchenne Muscular Dystrophy– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Delandistrogene moxeparvovec: Roche
Drug profiles in the detailed report…..
Mid-Stage Products (Phase II)
SRP 5051: Sarepta Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
WVE N531: Wave Life Sciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
EDG 5506: Edgewise Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Duchenne Muscular Dystrophy Key Companies
Duchenne Muscular Dystrophy Key Products
Duchenne Muscular Dystrophy- Unmet Needs
Duchenne Muscular Dystrophy- Market Drivers and Barriers
Duchenne Muscular Dystrophy- Future Perspectives and Conclusion
Duchenne Muscular Dystrophy Analyst Views
Duchenne Muscular Dystrophy Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Esophageal Cancer Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight, “Esophageal Cancer Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Esophageal Cancer pipeline landscape. It covers the Esophageal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Esophageal Cancer Research. Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight

Key Takeaways from the Esophageal Cancer Pipeline Report

On February 20, 2026, SOFIE conducted a study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo [¹⁸F]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection.
On February 18, 2026, Merck Sharp & Dohme LLC announced a phase 1/2 study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma.
DelveInsight’s Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Esophageal Cancer treatment.
The leading Esophageal Cancer Companies such as OncoTherapy Science, Inc./Shionogi & Co., Oncolys BioPharma Inc, Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu HengRui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, Suzhou Zelgen Biopharmaceuticals, Active Biotech/NeoTX Therapeutics, Rakuten Medical, HLB, CDR-Life, Schrodinger, BioSyngen, Guangzhou Bio-gene Technology, GO Therapeutics and others..
Promising Esophageal Cancer Therapies such as Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

Download for updates and be a part of the revolution in cancer care @ Esophageal Cancer Clinical Trials Assessment

Esophageal Cancer Emerging Drugs Profile

S-588410: OncoTherapy Science, Inc. /Shionogi & Co.

S-588410 is cancer peptide vaccine licensed out from OncoTherapy to Shionogi & Co., Ltd. It is a subunit vaccine commercialized by Shionogi. It is administered subcutaneously as an emulsion. The therapeutic candidate is a mixed peptide-cocktail vaccine of S-288310 and S-488410 comprising of five human leukocyte antigens (HLA)-A 2402-restricted epitope peptides derived from oncoantigen. The drug candidate is a new molecular entity. Currently, the drug is in the Phase III stage of its development for the treatment of Esophageal Cancer.

Telomelysin: Oncolys BioPharma Inc

Telomelysin (OBP-301) is a gene-modified oncolytic adenovirus in which selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. From the result of Phase I clinical study in the US, Telomelysin showed abscopal effect, which non-injected tumor as well as injected tumor was regressed in melanoma patients after single injection into one single tumor and found that not only increasing infiltration of CD8 and antigen presenting cells but diminishing Treg cells in injected tumor site. In preclinical studies for Telomelysin, Oncolys has demonstrated effective anti-tumor activity on various cancer cells, and there was no finding that may bring safety concerns in toxicological studies as well as bio-distribution study. Currently, the drug is in the Phase II stage of its development for the treatment of Esophageal Cancer.

LVGN-6051: Lyvgen Biopharma

LVGN6051 is xLinkAb anti-4-1BB (CD137) agonist mAb that has been designed to activate 4-1BB optimally in tumor microenvironment by targeting both 4-1BB and FcγRIIB. LVGN6051 strikes a balance between antitumor efficacy and safety by agonizing 4-1BB only in the presence of FcγRIIB, which is expressed on immune cells enriched in the tumor microenvironment, including B cells, dendritic cells and granulocytes. Currently, the drug is in the Phase I stage of its development for the treatment of Esophageal Cancer.

AN-0025: Adlai Nortye Biopharma

AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist, discovered by Eisai Co., Ltd. (Eisai), and designed to modulate the tumor microenvironment. Adlai Nortye has been granted exclusive rights concerning the research, development, manufacture and marketing in all regions outside of Japan and part of Asia (excluding China) by Eisai. It is currently under development for the treatment of locally advanced rectal cancer with radiation therapy in the ongoing global Phase II ARTEMIS study. We presented Phase 1b results for this indication at the European Society for Medical Oncology (“ESMO”) in October 2019, where combination therapy with AN0025 and RT/CRT was safe and enabled 36% of patients to achieve either a cCR or pathologic complete response (pCR). Currently, the drug is in the Phase I stage of its development for the treatment of Esophageal Cancer.

The Esophageal Cancer pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
Esophageal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.

Explore DelveInsight’s expert-driven report today! @ Esophageal Cancer Unmet Needs

Esophageal Cancer Companies

OncoTherapy Science, Inc./Shionogi & Co., Oncolys BioPharma Inc, Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu HengRui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, Suzhou Zelgen Biopharmaceuticals, Active Biotech/NeoTX Therapeutics, Rakuten Medical, HLB, CDR-Life, Schrodinger, BioSyngen, Guangzhou Bio-gene Technology, GO Therapeutics and others.

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download DelveInsight’s latest report to gain strategic insights into upcoming Esophageal Cancer Therapies and Developments, @ Esophageal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Esophageal Cancer Pipeline Report

Coverage- Global
Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.
Esophageal Cancer Therapies-Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab, and others.

Find out in DelveInsight’s exclusive Pipeline Report—access it now! @ Esophageal Cancer Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Esophageal Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Esophageal Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
S-588410: OncoTherapy Science, Inc. /Shionogi & Co.
Mid Stage Products (Phase II)
Telomelysin: Oncolys BioPharma Inc
Early Stage Products (Phase I)
LVGN-6051: Lyvgen Biopharma
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Esophageal Cancer Key Companies
Esophageal Cancer Key Products
Esophageal Cancer- Unmet Needs
Esophageal Cancer- Market Drivers and Barriers
Esophageal Cancer- Future Perspectives and Conclusion
Esophageal Cancer Analyst Views
Esophageal Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Cancer Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Metastatic Hormone Refractory Prostate Cancer Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Metastatic Hormone Refractory Prostate Cancer Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Metastatic Hormone Refractory Prostate Cancer pipeline landscape. It covers the Metastatic Hormone Refractory Prostate Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Hormone Refractory Prostate Cancer Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Metastatic Hormone Refractory Prostate Cancer Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/metastatic-hormone-refractory-prostate-cancer-pipeline-insight

Key Takeaways from the Metastatic Hormone Refractory Prostate Cancer Pipeline Report

On February 20, 2026- Novartis Pharmaceuticals conducted a Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).
On February 19, 2026- Amgen conducted a phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
On February 18, 2026- Hoffmann-La Roche initiated a phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician’s Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.
On February 17, 2026- Merck Sharp & Dohme LLC conducted a study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2.
On February 11, 2026- Kyntra Bio announced a phase 2 study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
DelveInsight’s Metastatic Hormone Refractory Prostate Cancer Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Metastatic Hormone Refractory Prostate Cancer treatment.
The leading Metastatic Hormone Refractory Prostate Cancer Companies such as Lantheus, Merck, Exelixis, Zenith Epigenetics, CellCentric, Karyopharm Therapeutics, Janux Therapeutics, Pfizer, Tavanta Therapeutics, Telix Pharmaceuticals, Jiangsu HengRui Medicine, SOTIO, Antev Ltd., Syntrix Pharmaceuticals, Regeneron Pharmaceuticals, Madison Vaccines, Phosplatin Therapeutics, MacroGenics, RedHill Biopharma, Xencor and others.
Promising Metastatic Hormone Refractory Prostate Cancer Therapies such as Enzalutamide, Patupilone, Prednisone, Docetaxel, Zactima (vandetanib), MDX-010, Denosumab, and others.

Want to know which companies are leading innovation in Metastatic Hormone Refractory Prostate Cancer? Dive into the full pipeline insights @ Metastatic Hormone Refractory Prostate Cancer Clinical Trials Assessment

The Metastatic Hormone Refractory Prostate Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Metastatic Hormone Refractory Prostate Cancer Pipeline Report also highlights the unmet needs with respect to the Metastatic Hormone Refractory Prostate Cancer.

Metastatic Hormone Refractory Prostate Cancer Overview

Metastatic Hormone-Refractory Prostate Cancer (mHRPC), also known as metastatic castration-resistant prostate cancer (mCRPC), is an advanced stage of prostate cancer in which the disease continues to progress despite the suppression of castrate levels. Initially, prostate cancer growth is typically driven by androgens, and hormone therapy is effective in slowing or stopping the disease. However, in mHRPC, cancer cells adapt and continue to grow even in the low-androgen environment. The cancer has also spread beyond the prostate gland to distant sites, most commonly bones and lymph nodes. This stage is associated with more aggressive behavior, increased symptom burden, and limited treatment options, requiring systemic therapies aimed at prolonging survival and improving quality of life.

Metastatic Hormone Refractory Prostate Cancer Emerging Drugs Profile

PNT2002: Lantheus

A radioconjugate composed of PNT2002, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity. Upon administration of lutetium Lu-177 PNT2002, the PNT2002 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells. The FDA has also granted fast track designation to the prostate specific membrane antigen (PSMA)-targeted therapy, 177Lu-PNT2002, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

Opevesostat: Merck

Opevesostat is an oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as prostate cancer. By inhibiting CYP11A1 enzyme activity, ODM-208 is designed to suppress the production of all steroid hormones and their precursors that may activate the androgen receptor signaling pathway. . Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

XL092: Exelixis

XL092 is a next-generation oral TKI that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and resistance to multiple therapies, including immune checkpoint inhibitors. XL092 is currently being developed for the treatment of advanced solid tumors, including genitourinary cancers, as a monotherapy and in combination with immune checkpoint inhibitors. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

ZEN 3694: Zenith Epigenetics

ZEN-3694 is an orally bioavailable, potent, small molecule BET inhibitor that selectively binds to both bromodomains of the BET proteins. The drug candidate was discovered and developed from a BET bromodomain inhibitor platform. Bromodomain and Extra-Terminal domain (BET) family of proteins (BRD2, BRD3, BRD4, and BRDT) can bind acetylated lysines through their tandem bromodomains to promote gene transcription. BET bromodomain inhibitors (BETi) target super enhancers and inhibit several programs involved in tumorigenesis such as proliferation, metastasis, invasion, and immune evasion. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

CCS1477: CellCentric

Inobrodib is a small molecule inhibitor, taken orally as a capsule. It inhibits p300 and CBP through binding into the conserved bromodomain of the twin proteins. This impacts the expression of key cancer drivers, including MYC and IRF4. Different cancer indications can be targeted by inobrodib as monotherapy or in combination with existing standard of care drugs. Currently, the drug is in Phase I/II stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

KPT-8602: Karyopharm Therapeutics

Eltanexor (KPT-8602) is a second generation oral SINE compound. Eltanexor functions by binding to and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. Eltanexor has demonstrated minimal brain penetration in animals, which has been associated with reduced toxicities in preclinical studies while maintaining potent anti-tumor effects. Currently, the drug is in Phase I/II stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

JANX 007: Janux Therapeutics

JANX007 is lead novel Tumor Activated T Cell Engager (TRACTr). JANX007 is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of tumors and is in the clinic for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company designed PSMA-TRACTr drug candidate as a single-masked TRACTr in which the PSMA-binding domain is unmasked. The T cell-specific binding domain (CD3e) is masked to help minimize CRS. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

PF07248144: Pfizer

PF-07248144, developed by Pfizer, is a small molecule antineoplastic agent that functions as a histone acetyltransferase (HAT) inhibitor. By inhibiting HAT, it potentially disrupts gene expression and cellular processes that promote cancer growth. Its mechanism of action targets the modification of histones, a key process in epigenetic regulation. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Hormone Refractory Prostate Cancer.

If you’re tracking ongoing Metastatic Hormone Refractory Prostate Cancer Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Metastatic Hormone Refractory Prostate Cancer Treatment Drugs

The Metastatic Hormone Refractory Prostate Cancer Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Hormone Refractory Prostate Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Hormone Refractory Prostate Cancer Treatment.
Metastatic Hormone Refractory Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Hormone Refractory Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Hormone Refractory Prostate Cancer market.

Metastatic Hormone Refractory Prostate Cancer Companies

Lantheus, Merck, Exelixis, Zenith Epigenetics, CellCentric, Karyopharm Therapeutics, Janux Therapeutics, Pfizer, Tavanta Therapeutics, Telix Pharmaceuticals, Jiangsu HengRui Medicine, SOTIO, Antev Ltd., Syntrix Pharmaceuticals, Regeneron Pharmaceuticals, Madison Vaccines, Phosplatin Therapeutics, MacroGenics, RedHill Biopharma, Xencor and others.

Metastatic Hormone Refractory Prostate Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Metastatic Hormone Refractory Prostate Cancer Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Metastatic Hormone Refractory Prostate Cancer Pipeline Report covers it all – check it out now @ Metastatic Hormone Refractory Prostate Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Hormone Refractory Prostate Cancer Pipeline Report

Coverage- Global

Metastatic Hormone Refractory Prostate Cancer Companies- Lantheus, Merck, Exelixis, Zenith Epigenetics, CellCentric, Karyopharm Therapeutics, Janux Therapeutics, Pfizer, Tavanta Therapeutics, Telix Pharmaceuticals, Jiangsu HengRui Medicine, SOTIO, Antev Ltd., Syntrix Pharmaceuticals, Regeneron Pharmaceuticals, Madison Vaccines, Phosplatin Therapeutics, MacroGenics, RedHill Biopharma, Xencor and others.

Metastatic Hormone Refractory Prostate Cancer Therapies- Enzalutamide, Patupilone, Prednisone, Docetaxel, Zactima (vandetanib), MDX-010, Denosumab, and others.
Metastatic Hormone Refractory Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Hormone Refractory Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Metastatic Hormone Refractory Prostate Cancer Treatment landscape in this detailed analysis @ Metastatic Hormone Refractory Prostate Cancer Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Metastatic Hormone Refractory Prostate Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic Hormone Refractory Prostate Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
PNT2002: Lantheus
Mid Stage Products (Phase II)
XL092: Exelixis
Early Stage Products (Phase I)
PF07248144: Pfizer
Preclinical and Discovery Stage Products
Inactive Products
Metastatic Hormone Refractory Prostate Cancer Key Companies
Metastatic Hormone Refractory Prostate Cancer Key Products
Metastatic Hormone Refractory Prostate Cancer- Unmet Needs
Metastatic Hormone Refractory Prostate Cancer- Market Drivers and Barriers
Metastatic Hormone Refractory Prostate Cancer- Future Perspectives and Conclusion
Metastatic Hormone Refractory Prostate Cancer Analyst Views
Metastatic Hormone Refractory Prostate Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Hormone Refractory Prostate Cancer Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Power Auto Exports Now Accepts Bitcoin and Crypto for U.S. and Global Delivery

Power Auto Exports, an automotive broker specializing in new and pre-owned vehicle sales for domestic buyers and international export, announced today that it now accepts Bitcoin (BTC), Ethereum (ETH), and other major cryptocurrencies as payment for cars and trucks. The option is available to buyers in the United States as well as international clients seeking American-sourced vehicles.

The move gives buyers a direct path to purchase without the delays or fees tied to traditional wire transfers and currency conversions. Transactions are processed securely through blockchain technology, allowing for faster settlement on high-value purchases.

“Our clients are increasingly operating in the digital asset space,” said J.D. (Lefty), General Manager at Power Auto Exports. “Accepting crypto removes real obstacles for buyers who want American vehicles but face friction with conventional payment methods. This is about meeting buyers where they already are.”

Power Auto Exports carries a broad selection of vehicles ready for immediate domestic sale or global shipment. The company handles export logistics directly, making it one of the few U.S. auto brokers to combine international vehicle sourcing with cryptocurrency payment acceptance.

Buyers can browse available inventory and learn more about the crypto payment process at www.powerexports.org/buy-cars-with-crypto or view listings on the company’s Facebook Marketplace profile.

About Power Auto Exports

Power Auto Exports is a Ft. Pierce, Florida-based automotive broker offering new and pre-owned cars and trucks for buyers across the United States and international markets. The company specializes in export logistics and works with clients globally to source, purchase, and ship American vehicles. Learn more at www.powerexports.org.

For inquiries, call 1+ 772-200-7865

Media Contact
Company Name: Power Auto Exports
Contact Person: J.D. (Lefty) General Manager
Email: Send Email
Phone: 1+ 772-200-7865
City: Ft. Pierce
State: Florida
Country: United States
Website: www.powerexports.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Power Auto Exports Now Accepts Bitcoin and Crypto for U.S. and Global Delivery

How Hidden Costs in Car Finance Agreements Could Still Be Affecting Drivers

“A UK driver reviewing car finance paperwork at a dealership. The scene reflects hidden costs, unclear commission, and potential mis-sold car finance agreements.”

Across the UK, many drivers are discovering that historic car finance agreements may contain terms that were never clearly explained. With a rise in financial awareness, Reclaim247 is helping people uncover signs of mis-sold car finance and explore car finance claims or PCP claims with no paperwork, no upfront cost, and no pressure.

Manchester, UK – February 24, 2026 – Hidden charges, vague interest terms, and commission-based arrangements are still causing problems for drivers years after they signed their car finance deals. While many assumed the matter was closed once the vehicle was paid off or returned, the long-term effects of mis-sold car finance are only now coming to light, with some drivers now exploring their eligibility for car finance compensation or a car finance refund.

Reclaim247 is working with UK drivers who want a clearer picture of how their past agreements were structured. In many cases, this review is uncovering signs of car finance mis-sold without the customer ever realising anything was wrong at the time.

“Most people were never told about broker commissions or how their interest rate was set,” said Andrew Franks, Co-Founder of Reclaim247. “They were just shown a monthly figure. Years later, when they look back, the numbers often don’t add up.”

Why Older Agreements Still Matter

Some drivers are finding that old agreements included costs that were never explained, such as:

Commission paid to brokers without disclosure
Interest rates increased without justification
A lack of real choice between finance products

These issues, according to the Financial Conduct Authority, are common signs of car finance mis-selling. The regulator has been reviewing car finance deals arranged between April 2007 and November 2024, focusing on practices such as:

Discretionary Commission Arrangements, where brokers raised interest rates to earn more commission
Unfairly High Commissions, where the broker’s payment far exceeded the value of the service provided
Limited Finance Options, where customers were led to believe they were comparing offers, when only one was presented

These issues are not always easy to spot. But if any of them applied to your agreement, you may be eligible for a car finance claim or a PCP claim.

Why PCP Claims Are Being Revisited

PCP claims are especially common due to how these agreements were presented. They often advertised low monthly costs, but many drivers did not fully understand the balloon payment or ownership terms at the end. In some cases, what looked like a flexible deal turned out to be more expensive than expected.

“PCP finance often looked affordable because of the monthly payment,” said Franks. “It was only at the end of the agreement that some drivers realised the full cost had never been clearly explained.”

A Simple, Free Way to Check

Reclaim247 offers a free tool that allows drivers to check for mis-sold car finance without needing documents. You don’t need to find the original lender or track down paperwork. Just provide your name, address and date of birth. The system searches for historical finance agreements and highlights any signs of mis-selling.

If signs of car finance mis-sold are found, the driver is referred to a regulated legal partner. There is no cost to start and no fee unless compensation is successfully recovered.

It’s Not Too Late to Act

Even if your car finance agreement ended years ago, the deal can still be reviewed. Many drivers are only now realising that something may have been wrong. Whether your agreement was a PCP or hire purchase deal, Reclaim247 can help you check if you’re eligible for a car finance claim.

Start your free check today at www.Reclaim247.co.uk

No paperwork needed. No upfront cost. No pressure.

About Reclaim247

Reclaim247 is a multi-award-nominated UK-based claims management service helping drivers check whether they were affected by mis-sold car finance. The company offers a simple, online tool for exploring car finance claims and PCP claims without the need for paperwork or upfront fees. With thousands of checks completed, Reclaim247 connects drivers to regulated legal partners to ensure fair outcomes for those impacted by car finance mis-selling.

Media Contact
Company Name: Reclaim247
Contact Person: Andrew Franks
Email: Send Email
Phone: 0333 041 0110
Address:3 Archway, Birley Fields, Hulme
City: Manchester
Country: United Kingdom
Website: https://www.reclaim247.co.uk/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: How Hidden Costs in Car Finance Agreements Could Still Be Affecting Drivers